More markers will be included in the database as and when they are made publicly available.
Furthermore, more markers will also be of great interest for estimating individual's kinships.
To some extent introducing more markers will result in a higher chance of also detecting spuriously deviating relative allele frequencies.
This density of marker information worked well for identifying the genetic basis of simple traits using GWAS, but more markers will be needed for analyzing complex traits.
Selection of nucleases that generate more markers will allow higher density linkage maps to be constructed, while improvements in sequencing chemistries and fragment preparation protocols will permit longer read lengths for comparative genome analysis.
In any case regular validation with phenotypic DST and clinical response remains required, since adding more markers will only improve sensitivity, if new strains (carrying new drug resistance conferring mutations) are introduced in the setting.
